Legend Biotech Corporation (LEGN) Ownership
LEGN ownership summary
as of October 18, 2026- Institutions
- 55.8% of shares outstanding
- Insiders
- 1.87% of shares outstanding
- Shares outstanding
- 194.5M
- Float
- 193.5M shares available to trade
- Short interest
- 19.92% 16.4M shares short
- Days to cover
- 7.36 short interest up 12.0% vs prior month
- Institutions 55.79%
- Insiders 1.87%
- Other investors 42.33%
LEGN top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | FMR Inc | 14.96% | 29.1M | $537.7M | +3.4M (+13.2%) | June 30, 2026 |
| 2 | Deerfield Management Co | 4.18% | 8.1M | $150.4M | +450,000 (+5.9%) | June 30, 2026 |
| 3 | Suvretta Capital Management, LLC | 3.64% | 7.1M | $130.7M | −511,029 (−6.7%) | June 30, 2026 |
| 4 | Hillhouse Capital Advisors, Ltd. | 3.08% | 6.0M | $110.6M | — | June 30, 2026 |
| 5 | BlackRock Inc | 2.43% | 4.7M | $87.3M | +41,991 (+0.9%) | June 30, 2026 |
| 6 | Westfield Capital Management Company, L.P. | 2.28% | 4.4M | $81.9M | −1.3M (−23.1%) | June 30, 2026 |
| 7 | Assenagon Asset Management SA | 1.97% | 3.8M | $70.8M | +3.8M (0.0%) | June 30, 2026 |
| 8 | The Goldman Sachs Group Inc | 1.88% | 3.7M | $67.7M | +2.2M (+150.1%) | June 30, 2026 |
| 9 | Point72 Asset Management, L.P. | 1.58% | 3.1M | $56.8M | −809,893 (−20.8%) | June 30, 2026 |
| 10 | Kynam Capital Management, LP | 1.54% | 3.0M | $55.5M | +1.4M (+90.4%) | June 30, 2026 |
| 11 | Artisan Partners Limited Partnership | 0.80% | 1.6M | $28.8M | −695,047 (−30.8%) | June 30, 2026 |
| 12 | State Street Corp | 0.77% | 1.5M | $27.7M | +332 (+0.0%) | June 30, 2026 |
| 13 | Capital Research & Mgmt Co - Division 3 | 0.73% | 1.4M | $26.3M | +772,804 (+119.3%) | June 30, 2026 |
| 14 | Morgan Stanley - Brokerage Accounts | 0.72% | 1.4M | $25.8M | +791,284 (+131.2%) | June 30, 2026 |
| 15 | Soleus Capital Management, L.P. | 0.62% | 1.2M | $22.3M | +1.2M (0.0%) | June 30, 2026 |
| 16 | Davern Capital Partners, L.P. | 0.61% | 1.2M | $22.0M | −123,226 (−9.4%) | June 30, 2026 |
| 17 | Driehaus Capital Management LLC | 0.60% | 1.2M | $21.4M | +1.2M (0.0%) | June 30, 2026 |
| 18 | Renaissance Technologies Corp | 0.51% | 1.0M | $18.5M | +478,400 (+91.7%) | June 30, 2026 |
| 19 | Ghisallo Capital Management LLC | 0.51% | 1.0M | $18.5M | +1.0M (0.0%) | June 30, 2026 |
| 20 | Matthews International Capital Management, LLC | 0.47% | 917K | $17.0M | −8,654 (−0.9%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 16.7M shares and 6 cut 3.5M.
LEGN top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Select Pharmaceuticals Port | 1.33% | 2.6M | $47.9M | +77,300 (+3.1%) | August 31, 2026 |
| 2 | Strategic Advisers Fidelity US TtlStk | 1.21% | 2.3M | $43.4M | +649,800 (+38.3%) | August 31, 2026 |
| 3 | Fidelity Select Health Care | 1.17% | 2.3M | $42.1M | +241,376 (+11.8%) | August 31, 2026 |
| 4 | Fidelity VIP Contrafund Initial | 0.97% | 1.9M | $34.9M | — | August 31, 2026 |
| 5 | Fidelity Emerging Markets | 0.89% | 1.7M | $32.0M | — | August 31, 2026 |
| 6 | Fidelity Contrafund | 0.78% | 1.5M | $27.9M | +461,888 (+44.1%) | August 31, 2026 |
| 7 | Fidelity OTC | 0.76% | 1.5M | $27.4M | −2.2M (−60.0%) | August 31, 2026 |
| 8 | Harbor Small Cap Growth Instl | 0.75% | 1.5M | $26.8M | +380,320 (+35.5%) | September 30, 2026 |
| 9 | iShares Biotechnology ETF | 0.66% | 1.3M | $23.6M | −9,688 (−0.8%) | September 30, 2026 |
| 10 | Fidelity Advisor Health Care I | 0.56% | 1.1M | $20.0M | +60,444 (+5.9%) | August 31, 2026 |
| 11 | iShares Core MSCI Emerging Markets ETF | 0.43% | 835K | $15.4M | −765 (−0.1%) | September 30, 2026 |
| 12 | Fidelity Puritan | 0.42% | 816K | $15.1M | −672,400 (−45.2%) | July 31, 2026 |
| 13 | HBM Healthcare Investments AG Ord | 0.37% | 721K | $13.3M | +120,600 (+20.1%) | June 30, 2026 |
| 14 | Fidelity China Region | 0.34% | 653K | $12.1M | — | August 31, 2026 |
| 15 | Strategic Advisers Fidelity Em Mkts | 0.33% | 639K | $11.8M | — | August 31, 2026 |
| 16 | JPM Global Healthcare C acc USD | 0.28% | 553K | $10.2M | −5,738 (−1.0%) | September 30, 2026 |
| 17 | Invesco Biotechnology & Genome ETF | 0.28% | 551K | $10.2M | — | September 30, 2026 |
| 18 | Jupiter Merian Glb Eq Abs Rt I USD Acc | 0.28% | 537K | $9.9M | −151,651 (−22.0%) | June 30, 2026 |
| 19 | Fidelity Blue Chip Growth | 0.25% | 484K | $8.9M | — | August 31, 2026 |
| 20 | Fidelity Advisor Equity Growth I | 0.24% | 473K | $8.7M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
LEGN insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-25 | Ying Huang | Sell | $8.77 | 9,936 | $87,139 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
LEGN shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns LEGN
Institutional investors own 55.8% of Legend Biotech's shares and insiders 1.87%. The largest holder is FMR Inc with 14.96% of the shares (29.1M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 6 reduced their stake in the latest filings. Short interest is 19.92% of the float, or 7.36 days of average trading volume. The share count rose 84.7% since 2018.
Related: LEGN analyst forecast, LEGN key metrics. See the LEGN stock overview for the latest quote and news.
LEGN ownership FAQ
Who owns the most Legend Biotech stock?
The largest shareholders of Legend Biotech are FMR Inc (14.96%), Deerfield Management Co (4.18%), Suvretta Capital Management, LLC (3.64%), Hillhouse Capital Advisors, Ltd. (3.08%), BlackRock Inc (2.43%).
What percentage of Legend Biotech is owned by institutions?
Institutions hold 55.8% of Legend Biotech's shares outstanding; insiders hold 1.87%.
Which funds own Legend Biotech?
The largest fund holders of Legend Biotech are Fidelity Select Pharmaceuticals Port (1.33%), Strategic Advisers Fidelity US TtlStk (1.21%), Fidelity Select Health Care (1.17%), Fidelity VIP Contrafund Initial (0.97%), Fidelity Emerging Markets (0.89%).
What is Legend Biotech's short interest?
16.4M shares of Legend Biotech were sold short, 19.92% of the float; at the average daily volume it would take 7.36 days to cover.
Are insiders buying or selling Legend Biotech?
Of the latest 1 reported insider transactions in Legend Biotech (since March 25, 2026), 0 were purchases and 1 were sales.
How many shares of Legend Biotech are outstanding?
Legend Biotech has 194.5M shares outstanding, of which 193.5M are in the public float.